PHIOGEN is a clinical stage company developing live biotherapeutic products for drug resistant and recurrent bacterial infections. Our lead product is being prepared to submit for an IND to support a Phase 1b/2a clinical trial Q3 of 2025 for recurrent urinary tract infections as our primary indication. We have developed the world's first immunizing therapeutic (treatment and prevention) that has shown repeated success in vitro, in vivo and even in human with 4 patients treated via FDA-approved emergency use case pathway. Technology Platform PHIOGEN has developed a 6-step technology platform that allows for the high-throughput selection and development of live biologic products(LBPs) to enhance anti-bacterial capabilities targeted against specific pathogen that result in hard to treat infections. Our lead product,PHI-UI-01 is unlike any concept in medicine as an immunizing-therapeutic to treat and prevent infections. Market in Women's Health Our primary target market is the Treatment for recurrent UTI (rUTI) market. In the US, UTIs account for over 10 million doctor visits annually with 80% of those visits being women. rUTIs are one of the most common bacterial infections worldwide with 1 in 2 women experience at least UTI in their lifetime and 40% having recurrent infections. With an estimated market size of approximately $6 billion, it encompasses both prescription medications and over-the-counter remedies. We aim to capture a significant share by offering a highly effective and innovative treatment and prevention options, improving patient-outcomes and reducing healthcare-costs.